NEW YORK (GenomeWeb) — Nanosphere said today that it has been selected by HealthTrust to provide multi-target molecular diagnostic tests for nearly 1,400 acute care facilities that are part of the HealthTrust membership.

Under the agreement, HealthTrust's members will have access to purchase Nanosphere's portfolio of Verigene multiplex molecular diagnostics tests for infectious diseases, including assays for detecting infections of the bloodstream, respiratory tract, and gastrointestinal tract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.